BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

889 related articles for article (PubMed ID: 17033112)

  • 1. Guidelines in the medical treatment of Helicobacter pylori infection.
    Dzieniszewski J; Jarosz M
    J Physiol Pharmacol; 2006 Sep; 57 Suppl 3():143-54. PubMed ID: 17033112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of three different second-line quadruple therapies including bismuth subcitrate in Turkish patients with non-ulcer dyspepsia who failed to eradicate Helicobacter pylori with a 14-day standard first-line therapy.
    Uygun A; Ozel AM; Yildiz O; Aslan M; Yesilova Z; Erdil A; Bagci S; Gunhan O
    J Gastroenterol Hepatol; 2008 Jan; 23(1):42-5. PubMed ID: 17559359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eradication rates of helicobacter pylori infection with second-line treatment: non-ulcer dyspepsia compared to peptic ulcer disease.
    Chung SJ; Lee DH; Kim N; Jung SH; Kim JW; Hwang JH; Park YS; Lee KH; Jung HC; Song IS
    Hepatogastroenterology; 2007 Jun; 54(76):1293-6. PubMed ID: 17629092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis and treatment of Helicobacter pylori infection.
    Bytzer P; Dahlerup JF; Eriksen JR; Jarbøl DE; Rosenstock S; Wildt S;
    Dan Med Bull; 2011 Apr; 58(4):C4271. PubMed ID: 21466771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Eradication of Helicobacter pylori infection in Europe: a meta-analysis based on congress abstracts, 1997-2002].
    Buzás GM; Józan J
    Orv Hetil; 2004 Oct; 145(40):2035-41. PubMed ID: 15559530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of Helicobacter pylori infection.
    Costa F; D'Elios MM
    Expert Rev Anti Infect Ther; 2010 Aug; 8(8):887-92. PubMed ID: 20695744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of ranitidine bismuth citrate, tetracycline and metronidazole with ranitidine bismuth citrate and azithromycin for the eradication of Helicobacter pylori in patients resistant to PPI based triple therapy.
    Altintaş E; Ulu O; Sezgin O; Aydin O; Camdeviren H
    Turk J Gastroenterol; 2004 Jun; 15(2):90-3. PubMed ID: 15334317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 'Rescue' therapies for the management of Helicobacter pylori infection.
    Di Mario F; Cavallaro LG; Scarpignato C
    Dig Dis; 2006; 24(1-2):113-30. PubMed ID: 16699270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapy of Helicobacter pylori infection].
    Treiber G
    Praxis (Bern 1994); 2000 May; 89(22):958-62. PubMed ID: 10893994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eradication therapies for Helicobacter pylori.
    Borody TJ; Shortis NP; Reyes E
    J Gastroenterol; 1998; 33 Suppl 10():53-6. PubMed ID: 9840019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Long-term course of reflux symptoms following Helicobacter pylori eradication].
    Peitz U; Raps S; Plein K; Leodolter A; Hotz Dagger J; Malfertheiner P
    Dtsch Med Wochenschr; 2004 Mar; 129(13):671-5. PubMed ID: 15026962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of quadruple regimen of clarithromycin added to metronidazole-containing triple therapy against Helicobacter pylori infection following clarithromycin-containing triple-therapy failure.
    Ueki N; Miyake K; Kusunoki M; Shindo T; Kawagoe T; Futagami S; Tsukui T; Inagaki H; Sakamoto C
    Helicobacter; 2009 Apr; 14(2):91-9. PubMed ID: 19298336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Helicobacter pylori infection. The Spanish consensus report. The Spanish Consensus Conference Group].
    Sainz R; Borda F; Domínguez E; Gisbert JP
    Rev Esp Enferm Dig; 1999 Nov; 91(11):777-84. PubMed ID: 10601771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Helicobacter pylori and peptic ulcer disease. Current evidence for management strategies.
    Chiba N; Lahaie R; Fedorak RN; Bailey R; Veldhuyzen van Zanten SJ; Bernucci B
    Can Fam Physician; 1998 Jul; 44():1481-8. PubMed ID: 9678277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Helicobacter pylori eradication: role of individual therapy constituents and therapy duration.
    Qasim A; O'Morain CA; O'Connor HJ
    Fundam Clin Pharmacol; 2009 Feb; 23(1):43-52. PubMed ID: 19207543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variables influencing outcome of Helicobacter pylori eradication therapy in South China.
    Cai W; Zhou L; Ren W; Deng L; Yu M
    Helicobacter; 2009 Oct; 14(5):91-6. PubMed ID: 19751433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How to proceed in Helicobacter pylori-positive chronic gastritis refractory to first- and second-line eradication therapy.
    Vaira D; Ricci C; Lanzini A; Perna F; Romano A; Corinaldesi R
    Dig Dis; 2007; 25(3):203-5. PubMed ID: 17827940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Helicobacter pylori eradication therapy.
    Suzuki H; Nishizawa T; Hibi T
    Future Microbiol; 2010 Apr; 5(4):639-48. PubMed ID: 20353303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori.
    Uygun A; Kadayifci A; Safali M; Ilgan S; Bagci S
    J Dig Dis; 2007 Nov; 8(4):211-5. PubMed ID: 17970879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Helicobacter pylori eradication therapy in chronic liver disease.
    Jung SW; Lee SW; Hyun JJ; Kim DI; Koo JS; Yim HJ; Park JJ; Lee HS; Chun HJ; Um SH; Choi JH; Kim CD; Ryu HS
    Dig Liver Dis; 2009 Feb; 41(2):134-40. PubMed ID: 18436489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.